FINDLAY, Ohio — Pharmacy students at the University of Findlay believe they’ve developed a new drug that could target the most aggressive form of cancer occurring in the brain.
The oral compound, RK15, targets glioblastomas, an aggressive brain cancer. The disease has a 10 percent, five-year survival rate.
If it’s successful, the medication would remove the need for risky medical procedures which require physical access to brain tissue, according to the University of Findlay.
Comments are closed.